Lisa Walter
Stock Analyst at RBC Capital
(3.14)
# 807
Out of 5,182 analysts
18
Total ratings
56.25%
Success rate
2.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lisa Walter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Outperform | $16 → $24 | $9.13 | +162.87% | 2 | Apr 17, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $42 → $30 | $13.50 | +122.22% | 4 | Apr 7, 2026 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $32 → $35 | $9.45 | +270.37% | 3 | Mar 19, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $140 → $130 | $85.20 | +52.58% | 2 | Mar 17, 2026 | |
| UTHR United Therapeutics | Maintains: Outperform | $587 → $643 | $566.99 | +13.41% | 3 | Feb 26, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $22 → $21 | $40.95 | -48.72% | 2 | Feb 25, 2026 | |
| EYPT EyePoint | Maintains: Outperform | $28 → $39 | $13.60 | +186.76% | 2 | Nov 6, 2025 |
MeiraGTx Holdings
Apr 17, 2026
Maintains: Outperform
Price Target: $16 → $24
Current: $9.13
Upside: +162.87%
Viridian Therapeutics
Apr 7, 2026
Maintains: Outperform
Price Target: $42 → $30
Current: $13.50
Upside: +122.22%
4D Molecular Therapeutics
Mar 19, 2026
Maintains: Outperform
Price Target: $32 → $35
Current: $9.45
Upside: +270.37%
Rhythm Pharmaceuticals
Mar 17, 2026
Maintains: Outperform
Price Target: $140 → $130
Current: $85.20
Upside: +52.58%
United Therapeutics
Feb 26, 2026
Maintains: Outperform
Price Target: $587 → $643
Current: $566.99
Upside: +13.41%
Apellis Pharmaceuticals
Feb 25, 2026
Maintains: Sector Perform
Price Target: $22 → $21
Current: $40.95
Upside: -48.72%
EyePoint
Nov 6, 2025
Maintains: Outperform
Price Target: $28 → $39
Current: $13.60
Upside: +186.76%